TickerTalks
Browse all tickers →
TickerTalks›$ILMN
ILILMN

Illumina, Inc.

$ILMN·$41B·Medical - Diagnostics & Research·Healthcare
$270.49-1.2%YTD+108.4%1Y+188.2%
Price updated 7m ago·X counts updated 4d ago
ILILMN
$ILMNIllumina, Inc.
$270.49-1.17%207 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $ILMN on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

207X posts · last 7 days
Sep 13Sep 27
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $ILMN's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data7 posts analyzed · as of 2026-09-15

Illumina joins the S&P 500 effective open on Sept 21 as part of the quarterly rebalance, alongside BE and Everpure. Pre-market strength (~+1.5%) confirms the index-add tailwind, though one caveat about post-add buyer-beware is noted.

Read what X is saying about $ILMN

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $ILMN — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersAcceleratingAI verdict · as of 2026-10-01

The move is getting stronger, with heavier trading behind it.

Illumina up 108% YTD on S&P 500 add and AI-genomics narrative — Keith Meister sold $57M across three September days.

Illumina is the global DNA sequencing leader that re-rated this year on the AI-genomics narrative and a successful index inclusion catalyst — S&P 500 add effective Sept 21. Up 108% YTD and at 97% of its 52-week range, the equity has done exactly what index-driven buying forces.

Two things in tension:

  • The mechanics are solid but not spectacular: Q revenue grew 5% YoY to $1.09B at a 21% operating margin with $251M FCF — this is modest growth, with four EPS surprises (+7-15%) telling you the sell side has caught up. ROIC at 14% is improving. The question is whether 108% YTD prices in a 2027-2028 AI-genomics inflection the P&L hasn't yet shown.
  • Insider signal is a yellow flag: Keith Meister sold $57M total across three September days ($26.1M + $16.6M + $14.5M). Meister (Corvex Management) is a prominent activist/strategic holder, and that selling into the index-add tailwind is the clearest institutional-level 'take gains' signal.

The Oct 29 Q3 print is where AI-attached genomics commentary has to meet the multiple. Clean beat with sequencer-attached revenue detail and the chart extends past $290; a flat update plus continued Meister selling and the index-add premium compresses.

Agrees with X sentimentThe S&P 500 index-add effective Sept 21 is factually right, and the pre-market strength matched the typical index-add tailwind. The 'post-add buyer-beware' caveat the thread cites is correct — index-add pops often fade. What the thread doesn't engage with is Keith Meister's $57M coordinated September selling, which is the single most important near-term signal.

What to watch: Oct 29 Q3 earnings — sequencer-attached revenue growth, AI-genomics commentary, operating margin trajectory, and whether the Meister cadence continues. Clean beat with AI-attached detail and $290+ opens; flat update plus continued Meister selling and the index-add premium compresses.

On the calendar: 2026-10-29 — Q3 2026 earnings

spx addednear 52w highinsider mega saleai genomics

Read the AI verdict on $ILMN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes DNA sequencing instruments, consumables, and arrays that underpin genomics research, oncology diagnostics, and reproductive health testing globally.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $ILMN.

Medical - Diagnostics & Research · Healthcare

Genetic testing, liquid biopsy, and multi-cancer early detection (MCED) platforms are growing through direct-to-consumer and employer wellness channels; reimbursement coverage expansion by CMS and commercial payers is the adoption bottleneck. Lab volume normalization post-COVID is complete; growth is now driven by novel test launches and test menu expansion for chronic disease management.

What this means for $ILMN

Neutral — Makes DNA sequencing instruments, consumables, and arrays that underpin genomics research, oncology diagnostics, and reproductive health testing globally.

Industry benchmark

18-name peer basket
+40.8%YTD
+68.6%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
33.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
13.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
21.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
6.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
34.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
67.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 30, 2026$1.31$1.23+6.5%
Q1 2026Apr 30, 2026$1.15$1.05+9.5%
Q4 2025Feb 5, 2026$1.35$1.24+8.9%
Q3 2025Oct 30, 2025$1.34$1.17+14.5%
Next earningsThu, Oct 29·consensus EPS $1.36

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$1.1B+4.8%68.2%21.3%$0.88$251.0M
Q4 FY25$1.2B+5.1%67.1%22.2%$2.18$267.0M
Q3 FY25$1.1B+0.3%67.6%21.3%$0.98$260.0M
Q2 FY25$1.1B-4.9%67.8%21.0%$1.50$211.0M

Forward consensus

5-year forecast · up to 16 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$4.6B$4.6B – $4.6B$5.35$5.33 – $5.3914
FY27$4.9B$4.8B – $5.0B$6.08$5.84 – $6.5414
FY28$5.3B$5.0B – $5.6B$7.02$6.68 – $7.7216
FY29$5.7B$5.6B – $5.9B$8.07$7.85 – $8.3211
FY30$6.0B$5.9B – $6.1B$8.96$8.72 – $9.2411

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.97%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+26.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+69.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 147.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.475-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 4Keith A. MeisterDirector119.5K sh$26.1MSellSep 3Keith A. MeisterDirector76.0K sh$16.6MSellSep 2Keith A. MeisterDirector68.1K sh$14.5MSellAug 27Keith A. MeisterDirector138.4K sh$31.7MSellAug 26Keith A. MeisterDirector106.5K sh$24.0MSellAug 25Keith A. MeisterDirector131.0K sh$29.5MSellAug 21Keith A. MeisterDirector31.6K sh$6.7MSellAug 20Keith A. MeisterDirector285.2K sh$61.0MSellAug 19Keith A. MeisterDirector95.0K sh$19.3MSellAug 18Wedel Christensen JakobSVP, Strategy/Corp Development1.0K sh$198K
1–10 of 23
+ 19 other (13 awards · 2 inkinds · 2 inthemoneys · 2 others) in window

See when $ILMN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KAgreement terminatedAug 138-K — Item 1.01: Material agreement · Item 1.02: Agreement terminated · Item 2.03: Material debt obligation
AI summary

Illumina, Inc. (ILMN) entered into a new $1 billion senior unsecured five-year revolving credit facility on August 13, 2026, with Bank of America as administrative agent; the facility includes a $50M swingline sublimit and a $75M letter-of-credit sublimit. The company simultaneously terminated an existing credit facility (Item 1.02) and the new arrangement is classified as creation of a direct financial obligation (Item 2.03). Illumina may expand commitments by up to an additional $500M with lender consent. The facility carries a variable rate tied to SOFR or the alternate base rate plus a spread based on debt ratings, with a maximum leverage ratio financial covenant — a standard refinancing at favorable terms for the genomics leader.

3New insider — initial holdingsAug 113
AI summary

Illumina (ILMN) filed a Form 3 initial statement of beneficial ownership for its Chief Legal Officer. The filing records the CLO's initial holdings in Illumina common stock as required upon appointment.

3New insider — initial holdingsJul 293
AI summary

An insider (Amount or Number of Shares Explanation of Responses: No secur) at ILMN (ILMN) filed a Form 3 on 2026-07-29 reporting initial or updated beneficial ownership. This is a routine insider reporting disclosure required within 10 days of becoming a 10%+ holder or new officer/director. It has limited standalone market impact but establishes the baseline for tracking future insider transactions.

3New insider — initial holdingsJun 233
AI summary

Daniel Skovronsky, MD/PhD (director, San Diego) filed a Form 3 initial beneficial ownership statement for Illumina as of June 16, 2026. Administrative disclosure.

8-KOfficer or director changeJun 238-K — Item 5.02: Officer or director change
AI summary

Illumina's Board expanded from 9 to 10 members and appointed Daniel Skovronsky, MD/PhD as an independent director effective June 16, 2026, with no third-party arrangement and no related transactions. Addition of a scientifically credentialed independent director.

8-KShareholder voteMay 268-K — Item 5.07: Shareholder vote
AI summary

Illumina's 2026 Annual Meeting on May 21, 2026 elected all 9 director nominees for one-year terms (Caroline Dorsa, Scott Gottlieb, David King, Keith Meister, Anna Richo, Philip Schiller, Susan Siegel, Jacob Thaysen, Scott Ullem), ratified Ernst and Young as independent auditor, and approved the advisory NEO compensation vote. Routine annual meeting; all nominees elected and auditor ratified.

3New insider — initial holdingsMay 223
AI summary

David P. King (director, San Diego CA) filed a Form 3 initial beneficial ownership statement for Illumina as of May 21, 2026. Administrative disclosure for newly reporting Illumina director.

+ 13 other (3 routine 8-Ks · 2 10-Qs · 2 13Gs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

The Top HealthTech Questions Landing on Our Desksetftrends.com·1d agoWhere Will Illumina Stock Be in 5 Years If Its AI Bet Pays Off?fool.com·2d agoREGN or ILMN: Which Is the Better Value Stock Right Now?zacks.com·2d agoIs the Options Market Predicting a Spike in Illumina Stock?zacks.com·3d agoIllumina (NASDAQ:ILMN) Reaches New 52-Week High – Here’s Whydefenseworld.net·6d ago

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NEO$A$GRAL$NTRA$TMO$DHR$GH$BLLN
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport